Kairos Pharma Ltd. (KAPA)
Kairos Pharma Ltd. Statistics
Share Statistics
Kairos Pharma Ltd. has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 513 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 9.61K, so 0.07% of the outstanding shares have been sold short.
| Short Interest | 9.61K |
| Short % of Shares Out | 0.07% |
| Short % of Float | 0.16% |
| Short Ratio (days to cover) | 0.13 |
Valuation Ratios
The PE ratio is -14.9 and the forward PE ratio is -8.93.
| PE Ratio | -14.9 |
| Forward PE | -8.93 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -43.12 |
| P/FCF Ratio | 333.25 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kairos Pharma Ltd..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06, with a Debt / Equity ratio of 0.
| Current Ratio | 0.06 |
| Quick Ratio | 0.06 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -17.49 |
Financial Efficiency
Return on equity (ROE) is 2.89% and return on capital (ROIC) is 273.8%.
| Return on Equity (ROE) | 2.89% |
| Return on Assets (ROA) | -1.88% |
| Return on Capital (ROIC) | 273.8% |
| Revenue Per Employee | - |
| Profits Per Employee | - |
| Employee Count | - |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Kairos Pharma Ltd.'s price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 53.12 |
| Average Volume (20 Days) | 2.24M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -1.71M |
| Net Income | -1.81M |
| EBITDA | -1.55M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.17 |
Balance Sheet
The company has 93.00K in cash and 0 in debt, giving a net cash position of 93.00K.
| Cash & Cash Equivalents | 93.00K |
| Total Debt | 0 |
| Net Cash | 93.00K |
| Retained Earnings | -6.32M |
| Total Assets | 5.00M |
| Working Capital | 3.07M |
Cash Flow
In the last 12 months, operating cash flow was 81.00K and capital expenditures 0, giving a free cash flow of 81.00K.
| Operating Cash Flow | 81.00K |
| Capital Expenditures | 0 |
| Free Cash Flow | 81.00K |
| FCF Per Share | 0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KAPA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -9.55% |
| FCF Yield | 0.35% |
Analyst Forecast
The average price target for KAPA is $9, which is 405.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 405.6% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 3.61 |
| Piotroski F-Score | 3 |